



## Update on Antifungal Therapy at St. Jude

### *Provided by*

**Speaker:** Joshua Wolf, MBBS, PhD; Jeffrey Rybak, PharmD, PhD; Katherine Knapp, MD

**Date/Time:** 2/2/2023 8:00:00 AM

**Location:** Webex

### ***Educational Objectives***

At the conclusion of this activity, the participant will be able to:

- 1 Describe the epidemiology and characterization of fungal infections in immunocompromised patients
- 2 Review the activity, adverse effects and therapeutic drug monitoring of antifungal agents
- 3 Review the recently updated St. Jude Guidelines for the Use of Antifungal Agents and highlight changes from previous guidelines

### ***Credit Designation***

St. Jude Children's Research Hospital designates this live activity for a maximum of **1.00 AMA PRA Category 1 Credit(s)<sup>™</sup>**. **Physicians should claim only the credit commensurate with the extent of their participation in the activity.**

### ***Accreditation Statement***

St. Jude Children's Research Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### ***Disclosure of Financial Relationships***

*The following speakers and other individuals in control of content have the following financial relationship(s) with commercial interests to disclose:*

*Joshua Wolf, MBBS, PhD: Other: Participation in industry sponsored research-Merck|Other: Participation in industry sponsored research-Astellas, Inc. |Grant or research support-Karius Inc. |Grant or research support-Pfizer Inc. - 05/24/2022*

*Jeffrey Rybak, PharmD, PhD: Nothing to disclose - 02/01/2023*

*Katherine Knapp, MD: Nothing to disclose - 12/27/2022*